Financiere des Professionnels Fonds d investissement inc. Sells 1,994 Shares of Johnson & Johnson (NYSE:JNJ)

Financiere des Professionnels Fonds d investissement inc. reduced its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 65,581 shares of the company's stock after selling 1,994 shares during the period. Financiere des Professionnels Fonds d investissement inc.'s holdings in Johnson & Johnson were worth $10,876,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. WealthTrak Capital Management LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. purchased a new position in shares of Johnson & Johnson in the fourth quarter worth approximately $29,000. Conquis Financial LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $33,000. Bernard Wealth Management Corp. purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $36,000. Finally, Runnymede Capital Advisors Inc. purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $38,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 0.3%

Shares of NYSE:JNJ traded up $0.49 during mid-day trading on Tuesday, reaching $155.76. The stock had a trading volume of 6,432,327 shares, compared to its average volume of 8,046,146. The firm has a market cap of $374.77 billion, a PE ratio of 17.33, a price-to-earnings-growth ratio of 2.36 and a beta of 0.41. The firm has a 50 day simple moving average of $153.67 and a two-hundred day simple moving average of $154.24. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. On average, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.34%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is presently 57.84%.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Raymond James Financial lowered their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Barclays lowered their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 16th. Finally, Wall Street Zen raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. Eleven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average target price of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.